FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * FRANKLIN RICHARD L   2. Issuer Name and Ticker or Trading Symbol Raptor Pharmaceutical Corp [RPTP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O RAPTOR PHARMACEUTICAL CORP., 5 HAMILTON LANDING, SUITE 160 3. Date of Earliest Transaction (Month/Day/Year) 09/09/2013 (Street) NOVATO, CA 94949 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 09/09/2013(1)   M   10,715 A $ 2.02 10,715 D   Common Stock 09/09/2013(1)   S   10,715 D $ 14.2402 (3) 0 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock options (right to buy)

$ 2.02

09/09/2013(1)

M

10,715

09/09/2010(2)

03/09/2020

Common Stock

10,715

$ 0

4,285 (8)

D

Stock options (right to buy)

$ 2.23

07/10/2012(4)

07/10/2018

Common Stock

34,969

34,969 (8)

D

Stock options (right to buy)

$ 2.97

02/28/2011(5)

10/12/2020

Common Stock

30,000

30,000 (8)

D

Stock options (right to buy)

$ 3.54

11/22/2010(6)

11/22/2020

Common Stock

90,000

90,000 (8)

D

Stock Options (right to buy)

$ 5.13

12/22/2011(4)

09/22/2021

Common Stock

30,000

30,000 (8)

D

Stock Options (right to buy)

$ 5.13

03/22/2012(5)

09/22/2021

Common Stock

90,000

90,000 (8)

D

Stock options (right to buy)

$ 5.49

12/25/2012(7)

09/25/2022

Common Stock

50,000

50,000 (8)

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
FRANKLIN RICHARD L C/O RAPTOR PHARMACEUTICAL CORP. 5 HAMILTON LANDING, SUITE 160 NOVATO, CA 94949	X

Signatures

/s/ Kim R. Tsuchimoto, Raptor Pharmaceutical Corp., Attorney-in-fact		09/11/2013
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 12, 2013.
(2)	Original options vest 6/48ths on September 9, 2010 and 1/48th per month thereafter.
(3)	This transaction was executed in multiple trades at prices ranging from $14.07 to $14.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(4)	Fully vested and exercisable.
(5)	Stock options start vesting 6/48ths from grant date and 1/48th per month thereafter.
(6)	Stock option vests 25% immediately and 75% pro rata over 36 months.
(7)	Stock options vest 25% quarterly.
(8)	The shares listed as owned in column 9 represent the total shares for each respective option. Previous reports reflected aggregate amounts of option shares in column 9. The holding lines included on this Form 4 are included solely to correct the breakdown of shares among various stock options and are not meant to reflect any change in beneficial ownership of option shares other than those reported as a transaction on this Form 4.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.